Amanote Research
Register
Sign In
Risk of Gastrointestinal Effects With COX-2 Inhibitors and NSAIDs: Study Conclusions Do Not Reflect Findings for Celecoxib
BMJ
doi 10.1136/bmj.331.7530.1473-d
Full Text
Open PDF
Abstract
Available in
full text
Date
December 15, 2005
Authors
Joe Feczko
Publisher
BMJ
Related search
Risk of Gastrointestinal Effects With COX-2 Inhibitors and NSAIDs: What Does Evidence From Randomised Trials Show About Celecoxib?
BMJ
Risk of Gastrointestinal Effects With COX-2 Inhibitors and NSAIDs: How Strong Is the Evidence?
BMJ
Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis
Archives of Internal Medicine
Editorial: Gastrointestinal Safety of COX-2 Selective and Nonselective NSAIDs-the Impact of the PRECISION Trial
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Editorial: Gastrointestinal Safety of COX-2 Selective and Nonselective NSAIDs-the Impact of the PRECISION Trial. Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Antitumor Effects of Celecoxib in COX-2 Expressing and Non-Expressing Canine Melanoma Cell Lines
Research in Veterinary Science
Veterinary
COX-1 and COX-2 Products in the Gut: Therapeutic Impact of COX-2 Inhibitors
Gut
Gastroenterology
Reduction in Cancer Risk by Selective and Nonselective Cyclooxygenase-2 (COX-2) Inhibitors
Journal of Experimental Pharmacology
Molecular Medicine
Pharmacology
Overexpression of COX-2 in Celecoxib-Resistant Breast Cancer Cell Lines
Journal of Surgical Research
Surgery
